Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That would be nice to get real figures, but doubt we'll get anything until filing.
It would be awesome if this was only 1/2 or 1/3 of their sales. Seems this pops to a quarter quick.
This was a long good read, Schena our boy putting us out front.
Brown, Shalon, and Smith [29], and Davis and [color=red]Schena [30] have argued that spotted microarrays have several advantages over the in situ chips designed by Affymetrix and Edwin Southerland[/color]. As we have seen in the case of GeneChip® design, in situ synthesis methods work with oligonucleotides, libraries of nucleic acid sequences of between 2–25 base pairs. On a GeneChip® a given gene might be represented by 15–20 different 25-mer oligonucleotides that serve as unique sequence-specific detectors. To be effective, the Affymetrix arrays require gene sequence information for specifying the de novo synthesis of the oligomers on the array. Spotted microarrays by contrast represent genes by single DNA fragments greater than several hundred base pairs in length, and virtually any length or origin. Moreover, spotted arrays do not require prior sequence knowledge but can be produced from both known and unknown cDNA and PCR fragments. Spotted microarrays, it is argued, are more flexible and more easily adaptable to a variety of research problems in genomics. Also to the point, spotted microarrays are inexpensive by comparison to Affymetrix chips [31]. Indeed, microarrayers based on the Brown-Shalon design could basically be constructed in-house by most major university research labs at a complete cost (in 1999) of around $60,000 [32]. Brown in fact has been so committed to the low cost production of microarrayers and an open source approach as a means to expedite the production of knowledge in genomics that he posted on his Stanford website all the details of manufacture for his microarray system, including all the software updates for operation of the scanning system, details on manufacturing and servicing the printing tips, and other fine points of the system.
Are all Arrayit equipment and supplies produced in this 15000 sq ft building? Or is some of it outsourced? Seems like lots of things produced in this small facility as rapidly as they are growing.
i almost got suckered into that. Thanks guys for the strong input to get me to cancel that sell at 0084. I would have been screwed. lol. Yes, I could see that dip coming to as we were really pushing the BB. It seems that reset the rsi a little.
thanks for replies all.
Observation: what do all the 10000 share trades account for throughout the day? Is this normal blocks, or is there something else going on?
agree
Affymetrix sold for 1.3 billion.what sets aryc apart from them and why would they be purchased for 3 to 5x affymetrix.
Thanks, GLTA
So your saying that google is willing to pay 4 to 6 billion dollars. Is this technology worth 4-6 billion?. Sales may currently be at 10 mil annual. What drives paying 4 to 6 Billion? Is the growth for this technology that extreme over the next few years?
GLTA
yeah that what I was thinking, seems possible I guess.
what was the share structure like when this was said?
Is it likely that the company could be buying back shares at these levels, or is that unlikely? Does there need to be a filing or announcement or something for them to do that?
LOL. yep keeps adding 1 to the count when refreshing.
Correct, that's just from this site.
If this goes to a quarter I will buy one.
Looks like they have sold almost 14000 of these pinner tests at 470.99 each. That's around 6.5 mil in pinner test alone.
holy shit chase is on
using scottrade
Whats up with the cck block at 33. No one taken that out.
just did a search rene schena owing irs. nothing came up. Sounds like only 1 person knows.
So, if a sell goes through and shows up red as a sell, and the price doesn't crash, what does that mean? Tomorrow it goes green to moves up? Someone was willing to continue to pay a higher price right without price crash? Is this called support? New to this.
How did they get 5 mil revolving credit? Real revs, real business, real growth?
Why not continue diluting if what general says is true. Why have they stopped? Real revenues and cash flow to sustain real business? hmmm. Why not continue to flood market with endless shares as majority of pinks?
I can read that, I think the message is that its DOD. It seems they are modifying their product prior to actual contract to ensure product meets their need like a rational partnership would do. Why receive 2.9 million worth of junk that only does half of whats required.
I sent stockcharts a request twice to add it back they've ignored the request so far.
How does the bid drop to .0017 when I still have an open order at .0018?
Will it hit 9.50?
Are they going to buy back shares with revenues they are generating?
How do you make money shorting a stock at .0002 when there is 800 mil on the bid?
Thanks
Only thing gonna bounce here is Nils on Big bubbas lap.
I was loaded. PR's were telling us of a turnaround. I bought into that. The 10q is due. It didn't come. I wanted to know why. Sent an e mail through there sight, got that reply. Didn't get a reply 3 days earlier, got one Thursday night though. Someone bought my crappy shares and then some and it dropped to 0004 still. Looks like Hans or what ever his freakin name is diluted again right into anything going on Friday. He's probably buddies with James Sikora at Tao Mining in Colombia FWIW. Columbia neck ties all around. Get em CBM. Done here.
So, here it is. F it
Borenore Info <info@borneore.com>
9:42 PM (11 hours ago)
to me
John
To answer your question
Do you guys got a rabbit to pull out of your hat. Getting a lot of flack about how this stock is crap and fake. Need some guidance here. Sounded like this was ready to make quite a turnaround, then silence. Is this still on track that may boost share holder value?
Borneo has not paid any of its headquarters staff for several months including the CFO, who has resigned several weeks ago now because of none payment of wages. The office in Hong Kong has been closed for non-payment as well I was told. The companies lawyers and auditors as of last week had not been paid for previous work and invoices, so there is no one to do the work on the Q. I believe Nils is trying to take the company dark now. There was never a chance of a turn around as the funds raised by these convertible notes this last year, very little went into the Indonesian operations to build any meaningful revenue to repay the convertible notes which triggered their conversions and dilution of the issued share base.
Website Admin
Anybody else get the Nils on the Run reply from company?
Got a response from somebody at the company. It would blow your mind if I posted. Then again maybe not. It's almost written in the same context as somebody on this board. LOl. Un f n believable.
http://www.vox.com/2015/4/1/8325301/immunotherapy-cancer
Memorial Sloan Kettering's Dr. Postow said for all the buzz about these drugs right now, there's a lot to be learned: "As excited as we are about this field, we know it doesn't help every patient, and we’re still trying to figure out who it helps, how it helps, and why." He continued: "It’s important for doctors and patients to realize this is not chemo."
Yeah it be nice to know, but no 10q or even 10q nt for 4 day extension.